Unlock stock picks and a broker-level newsfeed that powers Wall Street.
High Insider Ownership Growth Stocks To Know In April 2025

In This Article:

As the U.S. market navigates through a period of volatility fueled by recent tariff announcements, investors are keeping a keen eye on companies that can withstand economic headwinds. In this environment, growth stocks with high insider ownership often stand out as they suggest strong confidence from those closest to the company, potentially offering resilience and alignment with shareholder interests.

Top 10 Growth Companies With High Insider Ownership In The United States

Name

Insider Ownership

Earnings Growth

Super Micro Computer (NasdaqGS:SMCI)

14.2%

29.8%

Hims & Hers Health (NYSE:HIMS)

13.2%

21.8%

Duolingo (NasdaqGS:DUOL)

14.4%

37.3%

Coastal Financial (NasdaqGS:CCB)

14.5%

46.3%

Astera Labs (NasdaqGS:ALAB)

15.9%

61.3%

Clene (NasdaqCM:CLNN)

19.5%

63.1%

FTC Solar (NasdaqCM:FTCI)

31.6%

62.2%

BBB Foods (NYSE:TBBB)

16.2%

34.5%

Upstart Holdings (NasdaqGS:UPST)

12.7%

100.1%

Credit Acceptance (NasdaqGS:CACC)

14.4%

33.9%

Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

ARS Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions with a market cap of $1.23 billion.

Operations: The company's revenue is primarily derived from its pharmaceuticals segment, which generated $89.15 million.

Insider Ownership: 19%

Return On Equity Forecast: N/A (2027 estimate)

ARS Pharmaceuticals is experiencing significant growth, with earnings projected to increase 54.8% annually, outpacing the US market. The company recently became profitable, reporting a net income of US$8 million for 2024. Revenue surged to US$89.15 million from just US$0.03 million the previous year, driven by FDA approval of neffy, an innovative needle-free epinephrine nasal spray for allergic reactions. Despite trading below estimated fair value and no recent insider trading activity reported, ARS's strategic expansions and partnerships indicate robust potential for future performance.

NasdaqGM:SPRY Ownership Breakdown as at Apr 2025
NasdaqGM:SPRY Ownership Breakdown as at Apr 2025

Kaspi.kz

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Joint Stock Company Kaspi.kz, with a market cap of $17.92 billion, offers payments, marketplace, and fintech solutions for consumers and merchants in Kazakhstan, Azerbaijan, and Ukraine.